CoChat
Sign Up
Cited by 139Liver Disease Diagnosis and TreatmentLiver physiology and pathologyLiver Diseases and Immunity

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease

Open access
Sawada, Keisuke, Chung, Hak, Softic, Samir, Moreno-Fernandez, Maria E., Divanovic, Senad·2023·Cell Metabolism
DOI 10.1016/j.cmet.2023.10.009PMC PMC10680147
Open this paper in CoChat — free accountOpen PDF

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor for end-stage liver diseases with no available therapies. Dysregulated immune responses are critical culprits of MASLD pathogenesis. Independent contributions from either the innate or adaptive arms of the immune system or their unidirectional interplay are commonly studied in MASLD. However, the bidirectional communication between innate and adaptive immune systems and its impact on MASLD remain insufficiently understood. Given that both innate and adaptive immune cells are indispensable for the development and progression of inflammation in MASLD, elucidating pathogenic contributions stemming from the bidirectional interplay between these two arms holds potential for development of novel therapeutics for MASLD. Here, we review the immune cell types and bidirectional pathways that influence the pathogenesis of MASLD and highlight potential pharmacologic approaches to combat MASLD based on current knowledge of this bidirectional crosstalk.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2023.10.009

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 279

  1. Sarwar, 2018, Obesity and nonalcoholic fatty liver disease: current perspectives, Diabetes Metab. Syndr. Obes., 11, 533, 10.2147/DMSO.S146339 · DOI
  2. Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 · DOI
  3. Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin. Gastroenterol. Hepatol., 13, 643, 10.1016/j.cgh.2014.04.014 · DOI · Paper page
  4. Zhai, 2021, The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017, Sci. Rep., 11, 5195, 10.1038/s41598-021-84577-z · DOI
  5. Younes, 2018, Should we undertake surveillance for HCC in patients with NAFLD?, J. Hepatol., 68, 326, 10.1016/j.jhep.2017.10.006 · DOI
  6. Goyal, 2016, The progression and natural history of pediatric nonalcoholic fatty liver disease, Clin. Liver Dis., 20, 325, 10.1016/j.cld.2015.10.003 · DOI
  7. Mitsinikos, 2021, Pediatric nonalcoholic fatty liver disease, Pediatr. Clin. North Am., 68, 1309, 10.1016/j.pcl.2021.07.013 · DOI
  8. Jobira, 2021, Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome, PLoS One, 16, 10.1371/journal.pone.0245219 · DOI
  9. Wang, 2022, Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation, J. Clin. Pathol., 75, 443, 10.1136/jclinpath-2022-208246 · DOI
  10. Vos, 2022, Randomized placebo-controlled trial of losartan for pediatric NAFLD, Hepatology, 76, 429, 10.1002/hep.32403 · DOI
  11. Younossi, 2019, Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin. Gastroenterol. Hepatol., 17, 748, 10.1016/j.cgh.2018.05.057 · DOI
  12. Noureddin, 2018, NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances, Am. J. Gastroenterol., 113, 1649, 10.1038/s41395-018-0088-6 · DOI
  13. Adam, 2018, 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation, Transpl. Int., 31, 1293, 10.1111/tri.13358 · DOI · Paper page
  14. Nababan, 2022, Portal hypertension in nonalcoholic fatty liver disease: from pathogenesis to clinical practice, J. Clin. Transl. Hepatol., 10, 979, 10.14218/JCTH.2021.00593 · DOI
  15. Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat. Rev. Gastroenterol. Hepatol., 10, 330, 10.1038/nrgastro.2013.41 · DOI · Paper page
  16. Ferguson, 2021, Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus, Nat. Rev. Endocrinol., 17, 484, 10.1038/s41574-021-00507-z · DOI
  17. De Masi, 2023, Cyclo(His-Pro): a further step in the management of steatohepatitis, JHEP Rep., 5
  18. Sakaguchi, 2011, Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress, Drug Metab. Pharmacokinet., 26, 30, 10.2133/dmpk.DMPK-10-RV-087 · DOI
  19. Farrell, 2012, NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications, Gut Liver, 6, 149, 10.5009/gnl.2012.6.2.149 · DOI
  20. Alkhouri, 2009, Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal, Expert Rev. Gastroenterol. Hepatol., 3, 445, 10.1586/egh.09.32 · DOI
  21. Delli Bovi, 2021, Oxidative stress in non-alcoholic fatty liver disease. An updated mini review, Front. Med., 8, 10.3389/fmed.2021.595371 · DOI
  22. Ma, 2021, Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease, Antioxidants, 11, 91, 10.3390/antiox11010091 · DOI
  23. He, 2021, Gut microbiome-mediated alteration of immunity, inflammation, and metabolism involved in the regulation of non-alcoholic fatty liver disease, Front. Microbiol., 12, 10.3389/fmicb.2021.761836 · DOI
  24. Reccia, 2017, Non-alcoholic fatty liver disease: a sign of systemic disease, Metabolism, 72, 94, 10.1016/j.metabol.2017.04.011 · DOI
  25. Fotbolcu, 2016, Nonalcoholic fatty liver disease as a multi-systemic disease, World J. Gastroenterol., 22, 4079, 10.3748/wjg.v22.i16.4079 · DOI
  26. Marques, 2023, Overview of cellular and soluble mediators in systemic inflammation associated with non-alcoholic fatty liver disease, Int. J. Mol. Sci., 24, 2313, 10.3390/ijms24032313 · DOI
  27. Wang, 2021, Recent advances in adipose tissue dysfunction and its role in the pathogenesis of non-alcoholic fatty liver disease, Cells, 10, 3300, 10.3390/cells10123300 · DOI
  28. Cordeiro, 2020, Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?, Clin. Res. Hepatol. Gastroenterol., 44, 394, 10.1016/j.clinre.2019.10.001 · DOI
  29. Altajar, 2020, Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease, J. Clin. Transl. Hepatol., 8, 414
  30. Bhanji, 2017, Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis, Hepatology, 66, 2055, 10.1002/hep.29420 · DOI
  31. Giles, 2017, Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling, Nat. Med., 23, 829, 10.1038/nm.4346 · DOI
  32. Machado, 2015, Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease, PLoS One, 10
  33. Rinella, 2008, Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet, J. Lipid Res., 49, 1068, 10.1194/jlr.M800042-JLR200 · DOI
  34. Denda, 2002, Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet, Jpn. J. Cancer Res., 93, 125, 10.1111/j.1349-7006.2002.tb01250.x · DOI
  35. Boll, 2001, Mechanism of carbon tetrachloride-induced hepatotoxicity. Hepatocellular damage by reactive carbon tetrachloride metabolites, Z. Naturforsch., C: J. Biosci., 56, 649, 10.1515/znc-2001-7-826 · DOI
  36. Ito, 2007, Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet, Hepatol. Res., 37, 50, 10.1111/j.1872-034X.2007.00008.x · DOI
  37. Oates, 2023, Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease, Front. Immunol., 14, 10.3389/fimmu.2023.1095132 · DOI
  38. Davidson, 2001, Autoimmune diseases, N. Engl. J. Med., 345, 340, 10.1056/NEJM200108023450506 · DOI
  39. O'Shea, 2002, Cytokines and autoimmunity, Nat. Rev. Immunol., 2, 37, 10.1038/nri702 · DOI
  40. Carter-Kent, 2008, Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment, Am. J. Gastroenterol., 103, 1036, 10.1111/j.1572-0241.2007.01709.x · DOI
  41. Gasteiger, 2014, Interactions between innate and adaptive lymphocytes, Nat. Rev. Immunol., 14, 631, 10.1038/nri3726 · DOI
  42. Strutt, 2011, Control of innate immunity by memory CD4 T cells, Adv. Exp. Med. Biol., 780, 57, 10.1007/978-1-4419-5632-3_6 · DOI
  43. Swain, 2012, Expanding roles for CD4(+) T cells in immunity to viruses, Nat. Rev. Immunol., 12, 136, 10.1038/nri3152 · DOI
  44. Soudja, 2014, Memory-T-cell-derived interferon-gamma instructs potent innate cell activation for protective immunity, Immunity, 40, 974, 10.1016/j.immuni.2014.05.005 · DOI
  45. Jain, 2020, T cells instruct myeloid cells to produce inflammasome-independent IL-1beta and cause autoimmunity, Nat. Immunol., 21, 65, 10.1038/s41590-019-0559-y · DOI
  46. McDaniel, 2022, Effector memory CD4(+) T cells induce damaging innate inflammation and autoimmune pathology by engaging CD40 and TNFR on myeloid cells, Sci. Immunol., 7
  47. Huby, 2022, Immune cell-mediated features of non-alcoholic steatohepatitis, Nat. Rev. Immunol., 22, 429, 10.1038/s41577-021-00639-3 · DOI · Paper page
  48. Zhan, 2010, Roles of liver innate immune cells in nonalcoholic fatty liver disease, World J. Gastroenterol., 16, 4652, 10.3748/wjg.v16.i37.4652 · DOI
  49. Maher, 2008, Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis, Hepatology, 48, 670, 10.1002/hep.22399 · DOI
  50. Park, 2023, Major roles of Kupffer cells and macrophages in NAFLD development, Front. Endocrinol., 14, 10.3389/fendo.2023.1150118 · DOI
  51. Xu, 2023, Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions, Front. Cell Dev. Biol., 11, 10.3389/fcell.2023.1199519 · DOI
  52. Barreby, 2022, Macrophage functional diversity in NAFLD - more than inflammation, Nat. Rev. Endocrinol., 18, 461, 10.1038/s41574-022-00675-6 · DOI
  53. Rivera, 2007, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis, J. Hepatol., 47, 571, 10.1016/j.jhep.2007.04.019 · DOI · Paper page
  54. Ye, 2012, Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice, Gut, 61, 1058, 10.1136/gutjnl-2011-300269 · DOI · Paper page
  55. Kremer, 2010, Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis, Hepatology, 51, 130, 10.1002/hep.23292 · DOI
  56. Bieghs, 2013, The innate immune response during liver inflammation and metabolic disease, Trends Immunol., 34, 446, 10.1016/j.it.2013.04.005 · DOI
  57. Oates, 2019, Macrophage function in the pathogenesis of non-alcoholic fatty liver disease: the mac attack, Front. Immunol., 10, 2893, 10.3389/fimmu.2019.02893 · DOI
  58. Reid, 2016, Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation, PLoS One, 11, 10.1371/journal.pone.0159524 · DOI
  59. Seidman, 2020, Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis, Immunity, 52, 1057, 10.1016/j.immuni.2020.04.001 · DOI · Paper page
  60. Remmerie, 2020, Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver, Immunity, 53, 641, 10.1016/j.immuni.2020.08.004 · DOI · Paper page
  61. Kazankov, 2019, The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Nat. Rev. Gastroenterol. Hepatol., 16, 145, 10.1038/s41575-018-0082-x · DOI · Paper page
  62. McDonald, 2013, Kupffer cells and activation of endothelial TLR4 coordinate neutrophil adhesion within liver sinusoids during endotoxemia, Am. J. Physiol. Gastrointest. Liver Physiol., 305, G797, 10.1152/ajpgi.00058.2013 · DOI
  63. Cho, 2021, Two faces of neutrophils in liver disease development and progression, Hepatology, 74, 503, 10.1002/hep.31680 · DOI
  64. Paquissi, 2016, Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to interleukin-17 axis activation and new therapeutic targets, Front. Immunol., 7, 490, 10.3389/fimmu.2016.00490 · DOI
  65. Giles, 2015, IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression, Curr. Drug Targets, 16, 1315, 10.2174/1389450116666150531153627 · DOI
  66. Pulli, 2015, Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis, Antioxid. Redox Signal., 23, 1255, 10.1089/ars.2014.6108 · DOI · Paper page
  67. Gadd, 2014, The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease, Hepatology, 59, 1393, 10.1002/hep.26937 · DOI · Paper page
  68. Zhao, 2020, Neutrophils undergo switch of apoptosis to NETosis during murine fatty liver injury via S1P receptor 2 signaling, Cell Death Dis., 11, 379, 10.1038/s41419-020-2582-1 · DOI
  69. van der Windt, 2018, Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis, Hepatology, 68, 1347, 10.1002/hep.29914 · DOI
  70. Thomas, 2023, Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease, Cancer Med., 12, 3589, 10.1002/cam4.5185 · DOI
  71. Bernsmeier, 2017, Liver dendritic cells and NAFLD evolution: a remaining open issue, J. Hepatol., 66, 1120, 10.1016/j.jhep.2017.02.018 · DOI
  72. Sutti, 2015, CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis, Clin. Sci., 129, 797, 10.1042/CS20150053 · DOI
  73. Thomson, 2010, Antigen-presenting cell function in the tolerogenic liver environment, Nat. Rev. Immunol., 10, 753, 10.1038/nri2858 · DOI
  74. Heymann, 2016, Immunology in the liver--from homeostasis to disease, Nat. Rev. Gastroenterol. Hepatol., 13, 88, 10.1038/nrgastro.2015.200 · DOI · Paper page
  75. van der Zande, 2023, Dendritic cell-intrinsic LKB1-AMPK/SIK signaling controls metabolic homeostasis by limiting the hepatic Th17 response during obesity, JCI Insight, 8, 10.1172/jci.insight.157948 · DOI
  76. Bernsmeier, 2017, Liver dendritic cells and NAFLD evolution: a remaining open issue, J. Hepatol., 66, 1120, 10.1016/j.jhep.2017.02.018 · DOI
  77. Peng, 2017, Diversity of tissue-resident NK cells, Semin. Immunol., 31, 3, 10.1016/j.smim.2017.07.006 · DOI
  78. Tian, 2013, Natural killer cells in liver disease, Hepatology, 57, 1654, 10.1002/hep.26115 · DOI
  79. Luci, 2019, Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease, Front. Immunol., 10, 1192, 10.3389/fimmu.2019.01192 · DOI
  80. Diedrich, 2020, Characterization of the immune cell landscape of patients with NAFLD, PLoS One, 15, 10.1371/journal.pone.0230307 · DOI
  81. Kahraman, 2010, Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis, Hepatology, 51, 92, 10.1002/hep.23253 · DOI
  82. Cuff, 2019, The obese liver environment mediates conversion of NK cells to a less cytotoxic ILC1-like phenotype, Front. Immunol., 10, 2180, 10.3389/fimmu.2019.02180 · DOI
  83. Hoechst, 2009, Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor, Hepatology, 50, 799, 10.1002/hep.23054 · DOI
  84. Koo, 2020, Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma, Exp. Mol. Med., 52, 1209, 10.1038/s12276-020-0480-3 · DOI · Paper page
  85. Cui, 2019, NKT cells in neurological diseases, Front. Cell. Neurosci., 13, 245, 10.3389/fncel.2019.00245 · DOI
  86. Martin-Murphy, 2014, Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding, PLoS One, 9, 10.1371/journal.pone.0080949 · DOI
  87. Miyagi, 2010, Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet, J. Gastroenterol., 45, 1247, 10.1007/s00535-010-0272-y · DOI
  88. Han, 2023, Invariant natural killer T cells drive hepatic homeostasis in nonalcoholic fatty liver disease via sustained IL-10 expression in CD170(+) Kupffer cells, Eur. J. Immunol., 10.1002/eji.202350474 · DOI
  89. Liew, 2017, iNKT cells orchestrate a switch from inflammation to resolution of sterile liver injury, Immunity, 47, 752, 10.1016/j.immuni.2017.09.016 · DOI · Paper page
  90. Anson, 2012, Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice, J. Clin. Invest., 122, 586, 10.1172/JCI43937 · DOI
  91. Tang, 2022, Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver, Cell. Mol. Immunol., 19, 834, 10.1038/s41423-022-00872-3 · DOI
  92. Syn, 2010, Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease, Hepatology, 51, 1998, 10.1002/hep.23599 · DOI · Paper page
  93. Arrese, 2016, Innate immunity and inflammation in NAFLD/NASH, Dig. Dis. Sci., 61, 1294, 10.1007/s10620-016-4049-x · DOI
  94. Hirsova, 2021, Emerging roles of T cells in the pathogenesis of nonalcoholic steatohepatitis and hepatocellular carcinoma, Front. Endocrinol., 12, 10.3389/fendo.2021.760860 · DOI
  95. Gao, 2016, Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?, Gastroenterology, 150, 1704, 10.1053/j.gastro.2016.01.025 · DOI
  96. Chen, 2022, Role of innate lymphoid cells in obesity and insulin resistance, Front. Endocrinol., 13
  97. Brestoff, 2015, Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity, Nature, 519, 242, 10.1038/nature14115 · DOI · Paper page
  98. Eberl, 2015, Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology, Science, 348, aaa6566, 10.1126/science.aaa6566 · DOI · Paper page
  99. Dusseaux, 2011, Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells, Blood, 117, 1250, 10.1182/blood-2010-08-303339 · DOI
  100. Toubal, 2020, Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity, Nat. Commun., 11, 3755, 10.1038/s41467-020-17307-0 · DOI · Paper page
  101. Tosello-Trampont, 2016, NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice, Hepatology, 63, 799, 10.1002/hep.28389 · DOI · Paper page
  102. Gonzalez-Polo, 2019, Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis, Ann. Hepatol., 18, 366, 10.1016/j.aohep.2018.12.001 · DOI
  103. Xu, 2021, Group-2 innate lymphoid cells promote HCC progression through CXCL2-neutrophil-induced immunosuppression, Hepatology, 74, 2526, 10.1002/hep.31855 · DOI
  104. Li, 2018, Mucosal-associated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization, Front. Immunol., 9, 1994, 10.3389/fimmu.2018.01994 · DOI · Paper page
  105. Hegde, 2018, Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver, Nat. Commun., 9, 2146, 10.1038/s41467-018-04450-y · DOI · Paper page
  106. Corbett, 2020, Antigen recognition by MR1-reactive T cells; MAIT cells, metabolites, and remaining mysteries, Front. Immunol., 11, 1961, 10.3389/fimmu.2020.01961 · DOI
  107. Shuai, 2016, Adaptive immunity in the liver, Cell. Mol. Immunol., 13, 354, 10.1038/cmi.2016.4 · DOI
  108. Sanz, 2019, Challenges and opportunities for consistent classification of human B cell and plasma cell populations, Front. Immunol., 10, 2458, 10.3389/fimmu.2019.02458 · DOI · Paper page
  109. Raphael, 2015, T cell subsets and their signature cytokines in autoimmune and inflammatory diseases, Cytokine, 74, 5, 10.1016/j.cyto.2014.09.011 · DOI
  110. Moreno-Fernandez, 2021, PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease, Cell Metab., 33, 1187, 10.1016/j.cmet.2021.04.018 · DOI
  111. Kremer, 2006, Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis, Hepatology, 44, 216, 10.1002/hep.21221 · DOI
  112. Chackelevicius, 2016, Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis, World J. Gastroenterol., 22, 9096, 10.3748/wjg.v22.i41.9096 · DOI
  113. Gomes, 2016, Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma, Cancer Cell, 30, 161, 10.1016/j.ccell.2016.05.020 · DOI · Paper page
  114. Harley, 2014, IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice, Hepatology, 59, 1830, 10.1002/hep.26746 · DOI
  115. Tang, 2011, Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease, Clin. Exp. Immunol., 166, 281, 10.1111/j.1365-2249.2011.04471.x · DOI · Paper page
  116. Rai, 2020, Blocking integrin alpha(4)beta(7)-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis, J. Hepatol., 73, 1013, 10.1016/j.jhep.2020.05.047 · DOI · Paper page
  117. Ferreyra Solari, 2012, The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis, J. Clin. Immunol., 32, 611, 10.1007/s10875-011-9635-2 · DOI
  118. Luo, 2013, IFN-gamma deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet, Am. J. Physiol. Gastrointest. Liver Physiol., 305, G891, 10.1152/ajpgi.00193.2013 · DOI · Paper page
  119. Meng, 2012, Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice, Gastroenterology, 143, 765, 10.1053/j.gastro.2012.05.049 · DOI · Paper page
  120. Tan, 2013, IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation, J. Immunol., 191, 1835, 10.4049/jimmunol.1203013 · DOI
  121. He, 2017, The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice, BMC Immunol., 18, 33, 10.1186/s12865-017-0215-y · DOI
  122. Ma, 2007, A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury, Hepatology, 46, 1519, 10.1002/hep.21823 · DOI
  123. Wang, 2021, Bone marrow adipocytes: a critical player in the bone marrow microenvironment, Front. Cell Dev. Biol., 9
  124. Söderberg, 2011, Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis, APMIS, 119, 412, 10.1111/j.1600-0463.2011.02746.x · DOI
  125. Bhattacharjee, 2017, Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis, Hepatol. Commun., 1, 299, 10.1002/hep4.1041 · DOI · Paper page
  126. Wabitsch, 2022, Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD, J. Hepatol., 77, 748, 10.1016/j.jhep.2022.03.010 · DOI
  127. Koda, 2021, CD8(+) tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells, Nat. Commun., 12, 4474, 10.1038/s41467-021-24734-0 · DOI · Paper page
  128. McVey, 2022, NAFLD indirectly impairs antigen-specific CD8(+) T cell immunity against liver cancer in mice, iScience, 25, 10.1016/j.isci.2022.103847 · DOI
  129. Barrow, 2021, The emerging role of B cells in the pathogenesis of NAFLD, Hepatology, 74, 2277, 10.1002/hep.31889 · DOI · Paper page
  130. Zhang, 2016, Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells, J. Dig. Dis., 17, 464, 10.1111/1751-2980.12362 · DOI · Paper page
  131. McPherson, 2014, Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease, J. Hepatol., 60, 1055, 10.1016/j.jhep.2014.01.010 · DOI · Paper page
  132. Albano, 2005, Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis, Gut, 54, 987, 10.1136/gut.2004.057968 · DOI · Paper page
  133. Nobili, 2010, Oxidative stress parameters in paediatric non-alcoholic fatty liver disease, Int. J. Mol. Med., 26, 471, 10.3892/ijmm_00000487 · DOI
  134. McDaniel, 2021, Innate control of adaptive immunity and adaptive instruction of innate immunity: bi-directional flow of information, Curr. Opin. Immunol., 73, 25, 10.1016/j.coi.2021.07.013 · DOI
  135. Poggi, 2015, CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice, Int. J. Obes., 39, 977, 10.1038/ijo.2015.26 · DOI
  136. Chatzigeorgiou, 2014, Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation, Hepatology, 60, 1196, 10.1002/hep.27233 · DOI
  137. Kim, 2011, Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders, Diabetes, 60, 3159, 10.2337/db10-1805 · DOI
  138. Sun, 2018, OX40 regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis, Cell Rep., 25, 3786, 10.1016/j.celrep.2018.12.006 · DOI
  139. Guo, 2013, CD40 deficiency in mice exacerbates obesity-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance, Am. J. Physiol. Endocrinol. Metab., 304, E951, 10.1152/ajpendo.00514.2012 · DOI
  140. Wolf, 2014, Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in mice, Circulation, 129, 2414, 10.1161/CIRCULATIONAHA.113.008055 · DOI
  141. Aarts, 2019, Depletion of CD40 on CD11c+ cells worsens the metabolic syndrome and ameliorates hepatic inflammation during NASH, Sci. Rep., 9, 10.1038/s41598-019-50976-6 · DOI
  142. Wolf, 2012, CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies, PLoS One, 7, 10.1371/annotation/84102aae-770a-41ae-9c15-4736ed129c17 · DOI
  143. Poggi, 2011, CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice, Arterioscler. Thromb. Vasc. Biol., 31, 2251, 10.1161/ATVBAHA.111.231357 · DOI
  144. Villeneuve, 2010, A protective role for CD154 in hepatic steatosis in mice, Hepatology, 52, 1968, 10.1002/hep.23935 · DOI
  145. Item, 2017, Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function, Nat. Commun., 8, 480, 10.1038/s41467-017-00566-9 · DOI
  146. Wieser, 2018, Adipose type I interferon signalling protects against metabolic dysfunction, Gut, 67, 157, 10.1136/gutjnl-2016-313155 · DOI
  147. Wang, 2014, Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance, Hepatology, 59, 870, 10.1002/hep.26751 · DOI
  148. Alzaid, 2016, IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans, JCI Insight, 1, 10.1172/jci.insight.88689 · DOI
  149. Wang, 2013, Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice, Hepatology, 58, 603, 10.1002/hep.26368 · DOI
  150. Chan, 2021, A BAFF/APRIL axis regulates obesogenic diet-driven weight gain, Nat. Commun., 12, 2911, 10.1038/s41467-021-23084-1 · DOI
  151. Yamaguchi, 2010, Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice, Lab. Invest., 90, 1169, 10.1038/labinvest.2010.75 · DOI
  152. Unutmaz, 1994, Antigen-independent activation of naive and memory resting T cells by a cytokine combination, J. Exp. Med., 180, 1159, 10.1084/jem.180.3.1159 · DOI
  153. Geginat, 2002, TCR-independent proliferation and differentiation of human CD4+ T cell subsets induced by cytokines, Adv. Exp. Med. Biol., 512, 107, 10.1007/978-1-4615-0757-4_14 · DOI
  154. Saito, 2010, Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters, FEBS Lett., 584, 4865, 10.1016/j.febslet.2010.11.036 · DOI
  155. Croft, 2009, The significance of OX40 and OX40L to T-cell biology and immune disease, Immunol. Rev., 229, 173, 10.1111/j.1600-065X.2009.00766.x · DOI
  156. Vinay, 1998, Role of 4-1BB in immune responses, Semin. Immunol., 10, 481, 10.1006/smim.1998.0157 · DOI
  157. Elgueta, 2009, Molecular mechanism and function of CD40/CD40L engagement in the immune system, Immunol. Rev., 229, 152, 10.1111/j.1600-065X.2009.00782.x · DOI
  158. Schwarz, 2005, Biological activities of reverse signal transduction through CD137 ligand, J. Leukoc. Biol., 77, 281, 10.1189/jlb.0904558 · DOI
  159. Sun, 2007, A new class of reverse signaling costimulators belongs to the TNF family, J. Immunol., 179, 4307, 10.4049/jimmunol.179.7.4307 · DOI
  160. Croft, 2010, Control of immunity by the TNFR-related molecule OX40 (CD134), Annu. Rev. Immunol., 28, 57, 10.1146/annurev-immunol-030409-101243 · DOI
  161. Orabona, 2004, CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86, Nat. Immunol., 5, 1134, 10.1038/ni1124 · DOI
  162. Utley, 2020, CD28 regulates metabolic fitness for long-lived plasma cell survival, Cell Rep., 31, 10.1016/j.celrep.2020.107815 · DOI
  163. Venuprasad, 2003, CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response, Hum. Immunol., 64, 38, 10.1016/S0198-8859(02)00689-4 · DOI
  164. Venuprasad, 2001, Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression, Eur. J. Immunol., 31, 1536, 10.1002/1521-4141(200105)31:5<1536::AID-IMMU1536>3.0.CO;2-8 · DOI
  165. Zheng, 2008, Modulation of NKT cell development by B7-CD28 interaction: an expanding horizon for costimulation, PLoS One, 3, 10.1371/journal.pone.0002703 · DOI
  166. Woerly, 1999, Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin A complexes, J. Exp. Med., 190, 487, 10.1084/jem.190.4.487 · DOI
  167. Sharpe, 2002, The B7-CD28 superfamily, Nat. Rev. Immunol., 2, 116, 10.1038/nri727 · DOI
  168. Ursini, 2012, Improvement in insulin resistance after short-term treatment with abatacept: case report and short review, Clin. Rheumatol., 31, 1401, 10.1007/s10067-012-2034-0 · DOI
  169. Kwon, 1989, cDNA sequences of two inducible T-cell genes, Proc. Natl. Acad. Sci. USA, 86, 1963, 10.1073/pnas.86.6.1963 · DOI
  170. Vinay, 2011, 4-1BB signaling beyond T cells, Cell. Mol. Immunol., 8, 281, 10.1038/cmi.2010.82 · DOI
  171. Kim, 2008, 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation, J. Immunol., 180, 2062, 10.4049/jimmunol.180.4.2062 · DOI
  172. Lee, 2019, Reverse signaling of tumor necrosis factor superfamily proteins in macrophages and microglia: superfamily portrait in the neuroimmune interface, Front. Immunol., 10, 262, 10.3389/fimmu.2019.00262 · DOI
  173. Eissner, 2004, Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system, Cytokine Growth Factor Rev., 15, 353, 10.1016/j.cytogfr.2004.03.011 · DOI
  174. Eun, 2015, 4-1BB ligand signaling to T cells limits T cell activation, J. Immunol., 194, 134, 10.4049/jimmunol.1401383 · DOI
  175. Kim, 2020, 4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8(+) T cells in hepatocellular carcinoma, Hepatology, 71, 955, 10.1002/hep.30881 · DOI
  176. Paterson, 1987, Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts, Mol. Immunol., 24, 1281, 10.1016/0161-5890(87)90122-2 · DOI
  177. Wang, 2004, Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs, Tissue Antigens, 64, 566, 10.1111/j.1399-0039.2004.00300.x · DOI
  178. Soroosh, 2006, OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity, J. Immunol., 176, 5975, 10.4049/jimmunol.176.10.5975 · DOI
  179. Bretscher, 1999, A two-step, two-signal model for the primary activation of precursor helper T cells, Proc. Natl. Acad. Sci. USA, 96, 185, 10.1073/pnas.96.1.185 · DOI
  180. Blair, 2000, CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis, J. Exp. Med., 191, 651, 10.1084/jem.191.4.651 · DOI
  181. Peng, 1996, Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production, Eur. J. Immunol., 26, 1621, 10.1002/eji.1830260732 · DOI
  182. Lepreux, 2017, CD40 signaling and hepatic steatosis: unanticipated links, Clin. Res. Hepatol. Gastroenterol., 41, 357, 10.1016/j.clinre.2016.11.002 · DOI
  183. Takada, 2019, Integrin binding to the trimeric interface of CD40L plays a critical role in CD40/CD40L signaling, J. Immunol., 203, 1383, 10.4049/jimmunol.1801630 · DOI
  184. Peter, 2003, The CD95(APO-1/Fas) DISC and beyond, Cell Death Differ., 10, 26, 10.1038/sj.cdd.4401186 · DOI
  185. Suzuki, 1998, Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand, J. Exp. Med., 187, 123, 10.1084/jem.187.1.123 · DOI
  186. Boursalian, 2003, Mutation in fas ligand impairs maturation of thymocytes bearing moderate affinity T cell receptors, J. Exp. Med., 198, 349, 10.1084/jem.20030220 · DOI
  187. Isayama, 2016, Fas regulates macrophage polarization and fibrogenic phenotype in a model of chronic ethanol-induced hepatocellular injury, Am. J. Pathol., 186, 1524, 10.1016/j.ajpath.2016.02.006 · DOI
  188. Ottonello, 1999, Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes, J. Immunol., 162, 3601, 10.4049/jimmunol.162.6.3601 · DOI
  189. Hao, 2008, Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis, Immunity, 29, 615, 10.1016/j.immuni.2008.07.016 · DOI
  190. Alkhouri, 2015, Circulating soluble Fas and Fas ligand levels are elevated in children with nonalcoholic steatohepatitis, Dig. Dis. Sci., 60, 2353, 10.1007/s10620-015-3614-z · DOI
  191. Feldstein, 2003, Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis, Gastroenterology, 125, 437, 10.1016/S0016-5085(03)00907-7 · DOI · Paper page
  192. Crampton, 2010, Innate pathways to B-cell activation and tolerance, Ann. N. Y. Acad. Sci., 1183, 58, 10.1111/j.1749-6632.2009.05123.x · DOI
  193. Crouse, 2015, Regulation of antiviral T cell responses by type I interferons, Nat. Rev. Immunol., 15, 231, 10.1038/nri3806 · DOI
  194. Kiefer, 2012, Role of type I interferons in the activation of autoreactive B cells, Immunol. Cell Biol., 90, 498, 10.1038/icb.2012.10 · DOI
  195. Zhang, 2021, Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death, J. Exp. Med., 218, 10.1084/jem.20200887 · DOI
  196. Paolini, 2015, NK cells and interferons, Cytokine Growth Factor Rev., 26, 113, 10.1016/j.cytogfr.2014.11.003 · DOI
  197. Bekeredjian-Ding, 2005, Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN, J. Immunol., 174, 4043, 10.4049/jimmunol.174.7.4043 · DOI
  198. Akkaya, 2017, B cells produce type 1 IFNs in response to the TLR9 agonist CpG-A conjugated to cationic lipids, J. Immunol., 199, 931, 10.4049/jimmunol.1700348 · DOI
  199. Asselin-Paturel, 2005, Type I interferon dependence of plasmacytoid dendritic cell activation and migration, J. Exp. Med., 201, 1157, 10.1084/jem.20041930 · DOI
  200. Kim, 2016, Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease, Sci. Rep., 6

200 of 279 shown

Cited by

Sorted by citations

See all 139

Metadata

Authors
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S.
Affiliations
  • Cincinnati Children's Hospital Medical Center (US)
  • University of Kentucky (US)
Corresponding author
Divanovic, Senad
ORCID
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2023-11
Volume
35
Issue
11
Pages
1852-1871
ISSN
1550-4131 (ISSN-L)
DOI
10.1016/j.cmet.2023.10.009
PMC
PMC10680147
OpenAlex
W4388452323
Cited by
139
References
316
Citations by year
2026: 56 · 2025: 51 · 2024: 32
FWCI
5.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Heart Association (17POST33650045)
  • CCHMC
  • Cincinnati Children’s Research Foundation
  • National Institutes of Health (R01DK099222)
  • U.S. Department of Defense (W81XWH2010392)
  • American Diabetes Association (1-18-IBS-100)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
non-alcoholic fatty liver disease, innate immunity, adaptive immunity, liver inflammation, immune cell types, therapeutic target
MeSH terms
Fatty Liver, Humans, Inflammation, Metabolic Diseases, Pancreas, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review